Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Weaponising Exosomes for Breast Cancer treatment (ASX:IIQ)

- Successful Proof of Concept weaponizing exosomes for breast cancer treatment - Advancing optimisation of dosing and anti-tumour activity of exosomes Future milestones are further in vitro data...read more

Immutep - Excellent Survival Data from INSIGHT-003 Trial in NSCLC (ASX:IMM)

-- Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: ---- Median Overall Survival is 32.9...read more

Immutep - Positive Data from Phase II Trial in Soft Tissue Sarcoma (ASX:IMM)

-- Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma -- Over three-fold increase in tumour hy...read more

INOVIQ - Quarterly Business Update and Appendix 4C - September 2024 (ASX:IIQ)

Lodging this quarterly update, Chairman David Williams said: “Progress continued across our commercial, development and corporate activities. Promega is gaining new EXO-NET customers and there...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Key points: Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the ...read more

Immutep - Notice of Annual General Meeting/Proxy Form (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Annual report to shareholders (ASX:IMM)

On behalf of the Board, I’m pleased to present Immutep Limited’s Annual Report for the 2024 Financial Year. Immutep continues to be the leading biotech focused on the development of p...read more

Immutep - Appendix 4G and Corporate Governance Statement (ASX:IMM)

To view the appendix, download the attached PDF.

Immutep - IMP761 Progresses to Dose Escalation Portion of Ph1 Trial (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune...read more

Immutep - 2024 AGM & Key Dates (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2024 Annual General Meeting, (AGM) on Friday, 22 November 2024 commencin...read more

Immutep - Resignation of Non-Executive Director (ASX:IMM)

SYDNEY, AUSTRALIA – 4 October 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Immutep - Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed (ASX:IMM)

SYDNEY, AUSTRALIA – October 03, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing no...read more

Immutep receives A$3.6 million French R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - 24 September 2024 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 r...read more

Immutep - Data to be presented from Ph II trial in Soft Tissue Sarcoma (ASX:IMM)

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual Meeting EFTISARC-N...read more

Immutep - New Positive Efficacy Data for Efti in Head and Neck Cancer (ASX:IMM)

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA ou...read more

Viewing: 1 - 15 of 200 Previous | Next